SCHEDULE: Vanguard Group Reports 0% Stake in Coeptis Therapeutics

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Coeptis Therapeutics Holdings Inc. due to an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G regarding its holdings in Coeptis Therapeutics Holdings Inc. Common Stock.
• The filing indicates that The Vanguard Group now beneficially owns 0 shares, representing 0% of the class of securities.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• As a result of the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately.
• The Vanguard Group, Inc. itself no longer has, or is deemed to have, beneficial ownership over the securities previously held by these subsidiaries and/or business divisions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative development for Coeptis Therapeutics Holdings Inc. While the reason for the 0% ownership is an internal realignment at Vanguard, the direct reporting entity no longer holding shares removes a prominent institutional investor from the shareholder list, which can be perceived unfavorably by the market.

Negatives

• The Vanguard Group, a significant institutional investor, no longer reports beneficial ownership of Coeptis Therapeutics Holdings Inc. common stock, which could be perceived negatively by the market.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Coeptis Therapeutics Holdings Inc.'s future performance or The Vanguard Group's future investment intentions beyond the reporting change.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes that internal realignments within large asset managers like The Vanguard Group are not uncommon and often lead to changes in how beneficial ownership is reported across different entities within the same corporate structure. While this specific filing indicates The Vanguard Group, Inc. no longer directly reports ownership, it does not necessarily mean a complete divestment by all Vanguard-affiliated funds, as subsidiaries will now report separately. This reflects a trend towards more granular reporting by complex financial institutions.

Comparison to Industry Standards

• The Vanguard Group's reporting of 0% beneficial ownership for Coeptis Therapeutics Holdings Inc. is a standard disclosure for institutional investors when their direct holdings fall below the reporting threshold or are reallocated to other reporting entities within their corporate structure.
• This disaggregated reporting approach, as outlined in SEC Release No. 34-39538, is a common practice among large asset managers like BlackRock, State Street, and Fidelity, who manage vast portfolios through various funds and subsidiaries.

Stakeholder Impact

• Shareholders of Coeptis Therapeutics Holdings Inc. may view the departure of The Vanguard Group as a direct beneficial owner as a negative indicator, potentially impacting investor confidence.
• Investment professionals may scrutinize the implications of a major institutional investor's reported divestment, even if due to internal restructuring, for Coeptis Therapeutics Holdings Inc.'s stock performance.

Key Dates

Keywords

Coeptis Therapeutics Holdings Inc., Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Ownership Change, SEC Filing